---
title: It's here! The July 2026 edition of The Native Antigen Company Newsletter
---

Each month at The Native Antigen Company we bring you the most relevant infectious disease news from across the globe. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­    ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

| View in browser Please find the next edition of the Monthly Infectious Diseases Summary, our subjective look at the most important news of the month. Please let us know how you like it and if there is something interesting we missed by contacting us at nac.contact@lgcgroup.com Yellow Fever Resurges Across the Americas and Africa Yellow fever is making an alarming comeback, with WHO reporting nearly 100 confirmed cases across Africa and South America in the first five months of 2026 alone, following an eightfold surge in cases last year. The virus is expanding into previously unaffected areas, increasing concerns over wider spread and urban outbreaks. As symptoms often mimic dengue, malaria and other febrile illnesses, rapid and accurate diagnostics are becoming increasingly critical. Enhanced molecular and serological testing will play a pivotal role in early detection, outbreak monitoring and public health response, supporting vaccination programmes and helping to contain future epidemics before they escalate. Yellow fever - Global   See our full portfolio of Yellow fever antigens and antibodies here: Yellow Fever Virus antigens Archives - The Native Antigen Company, including matched pairs: Matched Pair Antibodies - The Native Antigen Company. Travel-Associated Dengue and Chikungunya Cases Continue to Rise in Europe EU/EEA countries have reported an increase in travel-associated dengue and chikungunya cases linked to popular tourist destinations in the Indian Ocean. Since 2025, over 107 dengue cases have been reported in travellers returning from the Maldives, while more than 166 chikungunya cases have been linked to travel to the Seychelles. Although recent data suggest a decline in imported cases, ECDC warns that favourable mosquito activity across parts of Europe could result in local transmission following introduction by infected travellers. These events highlight the ongoing need for robust surveillance and accurate diagnostic tools to support the detection and differentiation of arboviral infections. Communicable disease threats report, 19 - 26 June 2026, Week 26   Discover our growing list of VLPs including Dengue and Chikungunya here: Virus-Like Particles Archives - The Native Antigen Company. See how VLPs improve the sensitivity of diagnostics assays and aim vaccine research in our references. Bundibugyo Ebola Outbreak Escalates, Driving Demand for Advanced Diagnostics   The ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo has surpassed 900 confirmed cases and 230 deaths, making it one of the most significant infectious disease events of 2026. While transmission remains concentrated in eastern DRC, imported cases and secondary infections have also been reported in Uganda. With no approved vaccine or specific treatment currently available for Bundibugyo virus disease, rapid diagnosis remains central to outbreak control. The outbreak highlights the critical need for reliable molecular and serological assays to support case identification, surveillance, contact tracing and future vaccine development efforts. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda   We will soon be able to offer Bundibugyo proteins based on the currently circulating pathogen, sign up for the waiting list!   How will the AI change the NHS? LISTEN NOW TldR, bacterial hot rods and nullifying norovirus LISTEN NOW LISTEN NOW Tiny Bites, Big Consequences  LISTEN NOW Launch of Four New Recombinant Human Antibodies We are expanding our recombinant portfolio with three anti-Thyroglobulin (TG) IgG antibodies for autoimmune thyroid disease research and one anti-Chikungunya virus E2 IgM antibody for infectious disease diagnostics.   These new recombinant antibodies provide animal-free, reliable and reproducible reagents for research, IVD, and companion diagnostic assay development.   Visit our References page to view all the peer-reviewed publications we've collated.  The Native Antigen Company, LGC Unit 3, Oxford Technology Park, Kidlington, Oxford, Oxfordshire OX5 1GN, United Kingdom, +441865595230 Unsubscribe Manage preferences |
| --- |